{"disease":{"id":"stage-iii-hypopharyngeal-squamous-cell-carcinoma-ajcc-v7","name":"stage iii hypopharyngeal squamous cell carcinoma ajcc v7"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01810913","title":"Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":613,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02567422","title":"Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":43,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02775812","title":"Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01935921","title":"Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02381535","title":"Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}